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[571 ABSTRACT 
A method and apparatus for dynamically controlling the 
crystallization of proteins including a crystallization cham- 
ber or chambers for holding a protein in a salt solution, one 
or more salt solution chambers, two communication pas- 
sages respectively coupling the crystallization chamber with 
each of the salt solution chambers, and transfer mechanisms 
configured to respectively transfer salt solution between 
each of the salt solution chambers and the crystallization 
chamber. The transfer mechanisms are interlocked to main- 
tain the volume of salt solution in the crystallization cham- 
ber substantially constant. Salt solution of different concen- 
trations is transferred into and out of the crystallization 
chamber to adjust the salt concentration in the crystallization 
chamber to achieve precise control of the crystallization 
process. 
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DYNAMICALLY CONTROLLED 
CRYSTALLIZATION METHOD AND 
APPARATUS AND CRYSTALS OBTAINED 
THEREBY 
GOVERNMENT LICENSE RIGHTS 
The U.S. Government has a paid-up license in this inven- 
tion and the right in limited circumstances to require the 
patent owner to license others on reasonable terms as 
provided for by the terms of Contract No. NAS8-97010 
awarded by NASA, George C. Marshall Space Flight 
Center, and Grant No. 2R44GM53300-02 awarded by NIH 
and the National Institute of General Medical Sciences. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the formation of protein crystals 
and more particularly to a method and apparatus for dynami- 
cally controlling the process of forming protein crystals as 
well as to the crystals formed by the method and apparatus. 
2. Description of the Related Art 
The concept of rational drug design involves obtaining the 
precise three dimensional molecular structure of a specific 
protein to permit design of drugs that selectively interact 
with and adjust the function of that protein. Theoretically, if 
the structure of a protein having a specified function is 
known, the function of the protein can be adjusted as 
desired. This permits a number of diseases and symptoms to 
be controlled. For example, CAPTOPRIL is a well known 
drug for controlling hypertension that was developed 
through rational drug design techniques, CAPTOPRIL 
inhibits generation of the angiotension-converting enzyme 
thereby preventing the constriction of blood vessels. The 
potential for controlling disease through drugs developed by 
rational drug design is tremendous. 
X-ray crystallography techniques are utilized to obtain a 
“fingerprint”, i.e. the precise three-dimensional shape, of a 
protein crystal. However, a critical step to rational drug 
design is the ability to reliably crystallize a wide variety of 
proteins. Therefore, a great deal of time and money have 
been spent crystallizing proteins for analysis. Recent bio- 
technological developments in protein cloning, over 
expression, and affinity purification of proteins will likely 
increase the need for a reliable way in which to grow various 
protein crystals. Unfortunately protein crystallization is 
quite difficult. 
Protein crystallization involves the creation of a super- 
saturated protein solution under conditions that promote 
minimum protein solubility and the orderly transition of 
macromolecules from the solution into a crystal lattice. The 
variables that must be controlled precisely to promote crys- 
tal growth include temperature,  protein solution 
concentration, salt solution concentration and pH, for 
example. These variables are carefully controlled and opti- 
mum combinations thereof are determined through experi- 
mentation to yield superior crystals. 
The crystallization process generally involves three dis- 
tinct phases; nucleation, sustained crystal growth, and ter- 
mination of crystal growth. Nucleation is the initial forma- 
tion of an ordered grouping of a few protein molecules and 
requires a protein in a salt solution at a particular concen- 
tration. On the other hand, the continued growth phase 
consists of the addition of protein molecules to the growing 
faces of the crystal lattice and requires lower concentrations 
of salt solution than the nucleation phase. The termination 
S 
10 
1s 
20 
2s 
30 
3s 
40 
4s 
so 
5s 
60 
65 
2 
phase can be initiated by poisoning the growing lattice with 
denatured protein or a different protein, by depletion of the 
protein solution or by changing the salt concentration to a 
specified level. The protein is often referred to as a “reac- 
tant” and the salt solution is often referred to as a “reagent” 
in crystallization processes. 
It is considered desirable to obtain a small number of 
crystallization nuclei quickly that will grow slowly into full 
size crystals. Theoretically, this allows for a relatively large 
size of the resulting crystals, homogenous crystal order and 
morphology and balanced crystal dimensions. Therefore, it 
is desirable to begin crystallization with a particular salt 
concentration until nucleation is detected, at which point it 
is desirable to adjust the concentration of salt. Thus, one of 
the critical requirements of any protein crystallization pro- 
cess is the fine and dynamic control of the various param- 
eters that determine the concentration of the salt solution in 
which the target protein is suspended. This control requires 
the ability to attain nucleation conditions and the ability to 
modify the concentration of the salt solution without dis- 
turbing the crystallization process. 
There are several conventional techniques for forming 
protein crystals; for example, liquid diffusion, vapor diffu- 
sion and dialysis techniques. These processes are relatively 
slow and cannot readily be controlled dynamically. 
Therefore, these processes require complex and largo appa- 
ratus in order to control crystallization if crystallization can 
be controlled at all, Accordingly, it is desirable to overcome 
these limitations. 
Most conventional crystallization methods mix a protein 
solution with a crystallizing (or precipitant) solution to 
accomplish crystallization. In terms of mechanics, use is 
commonly made of syringes, stepping motors, valves of 
various types, membranes to separate solutions, and in one 
case, a gel to replace the membrane and act as a delaying 
filter device between solutions. U.S. Pat. Nos. 4,917,707, 
5,106,592, 5,641,681 and Microdialysis Crystallization 
Chamber, L. C. Sieker, J. Crystal Growth 90 (1988) 
349-357, the entire contents of which are incorporated 
herein by reference, disclose these concepts. 
It is known to “control” the crystallization process. 
However, only the movement of liquids via pumps, valves 
and syringes is controlled in conventional crystallization 
processes. This control creates a static condition (bath 
concentration) which is predefined for the protein in ques- 
tion. For example, U.S. Pat. No. 4,755,363, the entire 
contents of which are incorporated herein by reference, 
discloses delivering liquids at desired flow rates and 
concentrations, However, U.S. Pat. No. 4,755,363 fails to 
disclose changing conditions within the crystallization 
chamber (with the exception of temperature) once those 
conditions have been set and crystallization has begun. 
Temperature is an important parameter that can be con- 
trolled to optimize conditions separately for nucleation or 
growth. U.S. Pat. Nos. 4,755,363 and 5,362,325, the entire 
contents of which are incorporated herein by reference, are 
exemplary of patents disclosing temperature control in crys- 
tallization processes. U.S. Pat. No. 5,362,325 discloses 
varying the concentration of a crystallizing agent, over time, 
to produce a predetermined gradient in the concentration of 
the crystallizing agent. However, this reference fails to 
disclose dynamic control. 
Automation is a recent trend in crystallography. Robotics 
enables systematic pipetting of solutions and protein into 
crystal growth chambers on plates, so that a multiplicity of 
conditions can be examined more quickly and consistently. 
5,9r 
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The use of robotics frees valuable time for researchers. 
Another trend is the us- of semi-automated techniques to 
record results. 
Also, an inherent limitation in any crystallization process 
is the effects of molecular convection, thermal effects and 
buoyancy, all due to the earth’s gravitational field. 
Therefore, crystallization experiments have been proposed 
and conducted in microgravity (l/ooo g to %o,ooo g) on board 
the Space Shuttle, International Space Station, and other 
vehicles. Several patents disclose crystallization in micro- 
gravity to improve the size, morphology and diffraction 
quality of crystals. U.S. Pat. Nos. 5,362,325 and 4,755,363, 
which are incorporated herein by reference, are exemplary 
of patents disclosing microgravity crystallization. In fact, a 
low gravity environment is “crucial” (emphasis added) to 
the success of one apparatus (Sygusch, et al. J. Crystal 
Growth 162 (1996) 167-172). Early experiments indicate 
that larger and more homogenous crystals can be grown in 
microgravity environments by eliminating the effects of the 
earth’s gravitational field. However, the practical limitations 
of using current space vehicles, such as the Space Shuttle, 
render it difficult to use conventional apparatusimethods for 
crystallization in microgravity environments. Particularly, 
conventional apparatus are too large, are difficult to control 
remotely and automatically, have many moving parts that 
can fail, do not permit accurate change of solution concen- 
tration during the process and are not entirely reusable. Also, 
known processes require too much time to produce fully 
grown crystals. Therefore, it is desirable to overcome these 
deficiencies to permit crystal growth experiments in space 
under microgravity conditions. Also, conventional apparatus 
and methods do not facilitate experimentation in which the 
only variable is the presence or absence of the earth’s 
gravitational field because conventional crystallization 
apparatus must be modified significantly for use in space. 
Moreover, the foregoing methods and apparatus do not 
provide a dynamic control capability in either the earth’s 
gravitational field or in microgravity. 
SUMMARY OF THE INVENTION 
It is an object of the invention to control a protein 
crystallization process precisely and dynamically. 
It is another object to the invention to control a protein 
crystallization process remotely in real time. 
It is another object to the invention to control a protein 
crystallization process in a predetermined manner. 
It is another object of the invention to permit termination 
or reversal of a crystallization process. 
It is another object of the invention to reduce the size and 
number of moving parts in a crystallization method and 
apparatus. 
It is another object of the invention to produce protein 
crystals in a sealed system. 
It is another object of the invention to conduct protein 
crystallization experiments in space and on earth with iden- 
tical apparatus. 
It is another object of the invention to control crystalli- 
zation parameters in a sealed system without changing the 
pressure in the crystallization chamber. 
It is still further an object of the invention to produce large 
protein crystals in a very short period of time. 
The present invention is an apparatus and method for 
dynamically monitoring and controlling protein crystal 
growth. The present invention also identifies optimum crys- 
tallization conditions while using less experiments and sub- 
stantially less protein. 
61 
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The present invention creates a dynamic condition or 
control. “Dynamic Control” as used herein means that: (1) 
the crystallization process can be started at will, (2) several 
conditions (see, for example Durbin, S. & Feher, G. AnM 
Rev Phys Chem 47 (1996) 171-204, the entire contents of 
which are incorporated herein by reference) that are impor- 
tant for protein crystal growth (pH, temperature, 
conductivity, etc.) can be monitored, and implicit in this is 
the ability to determine molarity or salt concentration in the 
crystallization chamber by measurement of the latter 
parameter, (3) decisions can be made based upon these 
parameters, (4) these conditions can be very precisely con- 
trolled at any time during the crystallization process, (5) the 
crystallization process can be stopped when desired and (6) 
the process can be reversed if so desired. 
The operation of the present invention is compatible with 
the microgravity environment. A complex set of variables in 
the process of crystal growth are rigorously examined, 
manipulated and controlled so that microgravity is the only 
variable. The present invention has real time remote- 
controlled operative capabilities. The present invention is 
conservative in terms of cost containment for flights aboard 
the Space Shuttle and the International Space Station. Use of 
this invention conserves both money and valuable astronaut 
time. The present invention can remain on a space platform 
for many sets of experiments, while the protein crystalliza- 
tion chamber can return to earth with the proteins that are 
crystallized in space. New chambers, tubing and syringes 
can be delivered on the next flight pre-loaded. The invention 
can be readily miniaturized and thus the entire unit is less 
expensive to transport to and from space. 
In order to achieve these objects, a first aspect of the 
invention includes at least one crystallization chamber for 
holding a protein in a salt solution, one or more salt solution 
chambers, two communication passages respectively cou- 
pling the crystallization chamber with each of the salt 
solution chambers and transfer mechanisms configured to 
respectively transfer salt solution between each of the salt 
solution chambers and the crystallization chamber. The 
transfer mechanisms can work in cooperation to transfer 
equal amounts of salt solution into and out of the crystalli- 
zation chamber. 
A second aspect of the invention is a method of control- 
ling a protein crystallization process including placing a 
protein in a salt solution having a first concentration (or 
molarity) in a crystallization chamber, placing a salt solution 
of a second concentration (or molarity) in a first salt solution 
chamber, transferring salt solution between the salt solution 
chamber and the crystallization chamber to thereby adjust 
the concentration of protein solution in the crystallization 
chamber with respect to time. The initial concentration of 
the salt solution in the salt solution chamber is different than 
the initial concentration of the salt solution in the crystalli- 
zation chamber. Therefore, when salt solution is transferred, 
the concentration of the salt solution in the crystallization 
chamber changes. In this manner, the concentration of the 
salt solution in the crystallization chamber can be adjusted 
dynamically to provide optimum crystallization conditions 
with respect to time. 
The invention thus permits the crystallization process to 
be controlled easily, merely by operating the transfer mecha- 
nisms. This permits the methodiapparatus of the invention to 
be easily applied on earth or in micro gravity environments. 
A sealed system can be used without pressure change in the 
crystallization chamber. Also, the invention permits termi- 
nation or reversal of the crystallization process, variable salt 
concentration during the process, and conservation of the 
5,961,934 
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protein crystal sample for further experimentation. Further, 
the invention produces crystals in a reduced time with few 
moving parts and low power requirements. 
purpose, or the cover may comprise a button-shaped pro- 
trusion which is recessed for this purpose. Preferably, the 
cover comprises a button-shaped protrusion which is 
recessed. The recess serves as a compartment into which 
5 may be placed a solution containing a macromolecule for 
crystallization. The recess would then be covered by a 
other retainer may be used to hold the membrane in place. 
Alternatively, dialysis sack 15 is placed directly into the 
crystallization chamber for retention of the macromolecule. 
Dialysis sack 15 is illustrated schematically in FIG. 1. 
Additional salt solution is preferably disposed around dialy- 
sis sack 15. Other manners of retaining the macromolecule 
in the crystallization chamber will be readily apparent to one 
of ordinary skill in the art. 
A salt solution is loaded into syringe 16 (and optionally 
syringe 18 also). Accordingly, activation of motor 20 in a 
direction, causing yoke 24 to move in the direction of arrow 
salt solution stored in syringe 16 to be trans- 
BRIEF DESCRIPTION OF THE DRAWINGS 
The invention be described through a preferred membrane as described above, An elastic O-ring, gasket, or embodiment and the attached drawing in which: 
invention; and 
controlling the crystallization apparatus. 
FIG. 1 is a Plan view of a CrYstalliZation apparatus of the 
FIG. 2 is a schematic illustration of a controller for 
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DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT OF THE 
INVENTION 
FIG. 1 illustrates protein crystallization apparatus 10 in 
accordance with the invention. Apparatus 10 includes rigid will 
base plate 12, crysta11ization chamber l4 in which crysta1- ferred into crystallization chamber 14 while simultaneously 
lization is to occur, syringe 16, syringe "3 lead Screw 22, 20 causing salt solution to be transferred out of crystallization 
Yoke 24, and guide rods 26 and 28. Dialysis sack 15 is chamber 14 and into syringe 18. If the respective concen- 
removably disposed inside CrYstalliZation chamber 14. trations of the salt solution in crystallization chamber 14, 
Syringe 16 is coupled to crystallization chamber 14 by tube syringe 16, and syringe 18, are set to be of different 
17 serving as a c d u i t .  Syringe 18 is coupled to CrYstalli- predetermined values prior to crystallization, the concentra- 
zation chamber 14 by tube 19 serving as a conduit. Syringes 2~ tion of salt solution in crystallization chamber 14 can be 
16 and 18 serve as salt solution chambers as described in controlled dynamically, i.e. with respect to time merely by 
detail below. Plungers of syringe 16 and syringe 18 face in operating motor 20 in a desired manner with respect to time. 
opposing directions and are coupled to Yoke 24 which Serves For example, for certain proteins, it has been found that a 
as an interlock as described below. Further, Yoke 24 is salt concentration of about 0.15M (moles) facilitates crys- 
slidably disposed on guide rods 26 and 28. Lead Screw 22 is 30 tallization in the salt solution. Also, it has been found that it 
coupled to a shaft of motor 20 via vibration absorbing is desirable to approach this concentration very slowly and 
coupling 21 and is threadably engaged with Yoke 24. that the rate of approach can be critical in yielding desired 
Syringe 16, syringe 18, guide rod 26 and guide rod 28 are results. Therefore, in the preferred embodiment, crystalliza- 
fixedly coupled to base Plate 12 by mounting blocks 30 and tion chamber 14 can initially contain protein in a salt 
Screws 31 as Shown. Mounting block32 is fixed to base Plate 35 solution at a concentration of 1M (a concentration which 
12 by Screws 31 and has a bearing for Permitting rotation of does not permit crystallization.) Syringe 16 can initially 
lead screw 22 while axially fixing lead screw 22 to base plate contain a salt solution at a concentration of 0.1 mole, for 
12. Further, CrYstalliZation Chamber 14 and stepper motor 20 example. Further, syringe 18 can initially contain protein 
are also fixed to base Plate 12 by Screws 31. Spring 29 is solution at a concentration of 1 mole. With this arrangement 
coupled to base Plate 12 by Screw 31 at one end and to Yoke 40 to initiate a crystallization process, motor 20 can be acti- 
24 at another end to bias yoke 24 in one direction against vated to move yoke 24 in the direction of arrow x in FIG, 
threads of lead screw 22 to thereby minimize backlash when 1 to thereby transfer a small amount of low concentration 
yoke 24 is moved linearly as described below. salt solution from syringe 16 into crystallization chamber 14 
Activation of motor 20 will cause lead screw 22 to rotate and simultaneously transfer high concentration salt solution 
and thereby will cause yoke 24 to slide linearly along guide 45 from crystallization chamber 14 into syringe 18. It can be 
rods 26 and 28. Of course, linear motion of yoke 24 will seen that this procedure lowers the concentration of the salt 
cause the plunger of syringe 16 to move in one direction and solution in crystallization chamber 14. Of course, motor 20 
will cause the plunger of syringe 18 to move in the opposite can be activated in desired increments to cause the rate of 
direction through the same distance. Prior to a crystallization change of concentration of the solution in crystallization 
process, the target protein in a salt solution is loaded into 50 chamber 14 to be a desired value with respect to time. 
crystallization chamber 14. Further, motor 20 will be stopped when the concentration of 
Crystallization chamber 14 comprises a system for retain- the salt solution in crystallization chamber 14 has reached an 
ing macromolecules, such as proteins and DNA, but allow- optimum level for initiating crystallization, e.g. 0.15M. A 
ing for the passage of smaller molecules. A membrane or sensor can be placed in the crystallization chamber to 
permanent sieve having a molecular weight cut-off of a ss provide feedback to permit closed loop control. For 
predetermined value may be used in this regard. The mem- example, a sensor which measures the electrical resistance 
brane may be a part of a dialysis sack, or may be a sheet of or other electrical properties of the salt solution in crystal- 
dialysis membrane. In any case, the molecular weight cut-off lization chamber 14 can be used to indicate the concentra- 
should be lower than the molecular weight of the macro- tion of the solution in crystallization chamber 14 because 
molecule in the crystallization chamber, and should signifi- 60 electrical properties of the salt solution changes as the 
cantly reduce movement of the macromolecule out of the concentration changes. Of course, motor 20 can be operated, 
crystallization chamber. However, the membrane or sieve in response to the detected concentration in a pre- 
should not significantly hinder the movement of smaller programmed manner. The amount of salt solution that must 
molecules which might include ions and non-ionic solutes. be transferred to facilitate crystallization can be determined 
In preferred embodiments of the present invention, the 6s experimentally Or empirically. 
crystallization chamber comprises a cover which includes a Further, motor 20 can be operated to move yoke 22 in a 
recessed portion. The cover itself may be recessed for this reverse direction, i.e. a direction opposite arrow X, to cause 
5,961,934 
7 
salt solution to flow from syringe 18 into crystallization 
chamber 14 and from crystallization chamber 14 into 
syringe 16, to thereby raise the concentration of salt solution 
in crystallization chamber 14. In this manner, the concen- 
tration of salt solution in crystallization chamber 14 can be 
finely adjusted and raised or lowered to a value which will 
stop, or even reverse, the crystallization process. Therefore, 
precise dynamic control of the crystallization process can be 
achieved. 
Motor 20 can be a stepper motor such as Model No. 
STP42 ND 4BLVE-100 manufactured by EPSON AMERI- 
CAN. Also, the MffSD-V1 motor driver, manufactured by 
MODERN TECHNOLOGY, INC., can be used to control 
motor 20. A controller that facilitates predetermined pro- 
grammable control of the crystallization process is described 
in detail below. Any type of controller, such as a digital or 
analog programmable controller, can be used and any appro- 
priate motor can be used. For use in space, all components, 
including the motor and controller may have to be certified 
or approved by the appropriate regulatory authority. 
FIG. 2 is a schematic illustration of controller 40 for 
controlling motor 20 and thus the crystallization process. 
Controller 40 is constituted of control circuit 50, input 
connector 60, programming terminal 70, display 80, output 
connector 90, and input connector 100. Control circuit 50 
includes CPU (central processing unit) 52, I/O circuit 56, 
clock 54, and memory 53. Control circuit 50 can be a 
conventional microprocessor based device, such as a per- 
sonal computer or an industrial programmable controller, or 
control circuit 50 can be a dedicated solid state, handwired, 
digital, analog or mechanical controller, for example. Clock 
54 generates pulses at regular intervals in a conventional 
manner to provide timing for the operation of the other 
components. Memory 53 contains operating instructions for 
CPU 52 to carry out the crystallization process. The oper- 
ating instructions can be in the form of preprogrammed 
software in the case of a digital controller, hard wired 
components in the case of an analog controller or mechani- 
cal elements, such as cams, in the case of a mechanical 
controller. I/O circuit 56 provides an interface between CPU 
52 and external components such as motor 20, programming 
terminal 70, display 80 and any sensors or actuators. 
Input connector 60 includes three input connections for 
motor voltage (+M) a 5 volt D.C. logic voltage (+5), and a 
ground (G). Input connections of connector 60 are coupled 
to I/O circuit 56. Output connector 90 includes output 
connections for a first winding of motor 20 (Ml), a second 
winding of motor 20 (M2) and ground (G). Output connec- 
tions of connector 90 are coupled to I/O circuit 56 and to 
stepper motor 20 at (a) (as indicated in FIGS. 1 and 2.) 
Programming terminal 70 is coupled to CPU 52 through I/O 
circuit 56 to permit operating instructions to be input into the 
memory 53 of CPU 52. Programming terminal 70 can 
consist of any input device such as a keyboard, a touch 
screen, a bank of switches, push buttons, or the like. Once 
the operating instructions are stored in memory 53, pro- 
gramming terminal 70 can be disconnected from I/O circuit 
56 or can remain connected to I/O circuit 56. Display 80 also 
is coupled to CPU 52 through 10 circuit 56 and serves to 
display operating parameters or status relating to the opera- 
tion of controller 40. For example, display 80 can be a CRT, 
LCD display, LED display or similar device. Of course, 
display 80 is optional. 
Once the operating instructions are stored in memory 53 
through conventional programming and storage techniques, 
the proper input voltage is supplied to input connector 60 
and output connector 90 is coupled to stepper motor 20, 
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controller 40 can control motor 20 to operate in a predeter- 
mined manner with respect to time to thereby control the 
crystallization process in a desired manner. Of course, if the 
initial concentration of salt solution in syringes 16 and 18 
s and the initial concentration of salt 3solution in crystalliza- 
tion chamber 14 are known and the volumes of crystalliza- 
tion chamber 14, syringe 16, and syringe 18 are known, the 
operating instructions stored in memory 53 can be config- 
ured to control the crystallization process; i.e. the concen- 
i o  tration of salt solution in crystallization chamber 14 in a 
dynamic manner with respect to time to provide desirable 
crystallization conditions at all times. Input connector 100 
includes inputs I,-I4 for coupling additional inputs, such as 
limit switches, sensors, and the like, to CPU 52 through I/O 
IS circuit 56. This permits closed loop control to be achieved, 
based on the state of the crystallization process or other 
variables. Additionally, these inputs can be coupled to 
swiches, or the like, for initiating, terminating, interrupting 
or changing the operation of CPU 52. Of course the oper- 
20 ating instructions stored in memory 53 can be programmed 
in accordance with any desired operation and external inputs 
or outputs. 
Crystallization experiments were conducted using an 
apparatus according to the invention. The proteins crystal- 
25 lized were carboxy peptidase-A (CPA) and concanavalin-A 
(CON-A). The crystallization chamber in the apparatus used 
for the experiments has a volume of 1 ml. The target proteins 
were suspended in a dialysis bag placed in the crystallization 
chamber and having a volume of 50 pl. 
In the experiments with CPA, the protein was disposed in 
the dialysis bag in a solution of 1.2M LiCl at a pH of 7.5 at 
a protein concentration of 12 mgiml. The dialysis bag was 
then placed in the crystallization chamber and the remainder 
of the crystallization chamber was filled with 1.2M solution 
35 of LiCl at a pH of 7.5. One of the syringes was loaded with 
a 0.1M solution of LiCl at a pH of 7.5 which was injected 
into the crystallization chamber. Several trials were con- 
ducted under these initial conditions with the amount of salt 
solution transferred from the syringe to the crystallization 
40 chamber being different in each trial. In each trial, the 
amount of salt solution transferred from the crystallization 
chamber was equal to the amount of salt solution transferred 
to the crystallization chamber, as described above. Each of 
the mixing times was under 1 minute. 
The results of the crystallization tests for CPA are pre- 
sented below in Table 1. 
30 
45 
TABLE 1 
so ml. of .1M 
Trial # initial CC solution LiCLl7.5 injected Results 
1 1.2M LiC117.5 3 ml. No crystals 
2 1.2M LiC117.5 4 ml. No crystals 
3 1.2M LiC117.5 5 ml. Large crystals 
55 4 1.2M LiC117.5 6 ml. Large crystals 
5 1.2M LiC117.5 6.5 ml. Large crystals 
It can be seen that trials 1 and 2 did not lower the 
concentration of the salt solution in the crystallization cham- 
60 ber enough to produce large crystals. However, in trials 3-5 
larger amounts of low concentration salt solution were 
transferred into the crystallization chamber and thus the 
concentration of salt solution was lowered into a range in 
which the protein can come out of solution to form large 
65 crystals. The results of trials 3-5 compared favorably to a 
control trial using a conventional dialysis method of crys- 
tallization. In the control trial a 50 pl dialysis bag was filled 
5,961,934 
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with CPA at a concentration of 12 mgiml in 1.2M LiCl at a 
pH of 7.5. The dialysis bag was then suspended in 1 ml of 
0.1M LiCl at a pH of 7.5. While the control trial yielded 
large crystals it could not be dynamically or remotely 
controlled because once the dialysis bag was placed in the 
salt solution, crystallization conditions could not be altered. 
In the experiments with Con-A, the protein was disposed 
in the dialysis bag at a concentration of 30 mgiml in 1M 
NaCl at a pH of 6.5 which was injected into the crystalli- 
zation chamber. The dialysis bag was placed in the crystal- 
lization chamber and the crystallization chamber was filled 
with 1M NaCl at a pH of 6.5. One of the syringes was loaded 
with a 0.1M solution of NaNo, at a pH of 6.5. Several trials 
were conducted under these initial conditions with the 
amount of salt solution transferred from the syringe to the 
crystallization chamber being different in each trial. In each 
trial, an amount of salt solution was transferred out of the 
crystallization chamber, the amount being equal to the 
amount of solution transferred into the crystallization cham- 
ber. The results of the crystallization tests for Con-A are 
presented below in table 2. 
TABLE 2 
initial CC ml. of .1M NaNo,/ 
Trial # solution 6.5 injected Results 
1 1M NaC116.5 2.5 1000’s small crystals 
2 1M NaC116.5 3.5 100’s small crystals 
3 1M NaC116.5 4.5 Few Large crystals 
4 1M NaC116.5 5.5 Few Large crystals 
5 1M NaC116.5 6.5 Few Large crystals 
It can be seen that trials 1 and 2 did not lower the 
concentration of the salt solution in the crystallization cham- 
ber enough to produce large crystals. However, in trials 3-5 
larger amounts concentration salt solution were transferred 
into the crystallization chamber and thus the concentration 
of salt solution was lowered into a range in which the protein 
can come out of solution to form large crystals. The results 
of trials 3-5 compared favorably to a control trial using a 
conventional dialysis method of crystallization. In the con- 
trol trial a 50 pl dialysis bag was filled with CON-A at a 
concentration of 30 mgiml in 1.OM NaCl at a pH of 6.5. The 
dialysis bag was thus suspended in 1 ml of 0.1M NaNo at a 
pH of 6.5. While the control trial yielded large crystals it 
could not be dynamically or remotely controlled because 
once the dialysis bag was placed in the salt solution, 
crystallization conditions could not be altered. The final 
molarity in the crystallization chamber in each trial has not 
been measured or determined empirically. 
The protein in the crystallization chamber can be a 
membrane bound protein. In such case, a detergent can be 
introduced into the crystallization chamber at an appropriate 
time, by a microsyringe, or the like, to separate the protein 
from the membrane. The protein can be confined within a 
dialysis bag or the like or can be freely suspended in solution 
in the crystallization chamber. 
In the preferred embodiment, syringes are used to store 
salt solution and plungers of the syringes are moved to 
transfer the salt solution. However, any arrangement for 
delivering salt solution to and from the crystallization 
chamber(s) can be used. For example, two or more 
reservoirs, each pair having pumps which are electrically or 
mechanically interlocked, can be used or a single reservoir 
or syringe can be used and any excess salt solution can be 
allowed to drain into a reservoir or the atmosphere or a valve 
arrangement can be used. The salt solution may be trans- 
10 
ferred to a manifold. A bank of valves may be connected to 
the manifold in such a way that salt solution may flow 
through the valves in open position to a multiplicity of 
crystallization chambers. In this embodiment multiple crys- 
s tallizations may be carried out simultaneously. Also, the 
yoke interlocks the syringes in the preferred embodiment. A 
membrane, sieve or other suitable device may be placed at 
the outside entrance to the crystallization chamber. The 
protein solution might then be placed in the crystallization 
i o  chamber. In still other embodiments, the salt solution may be 
transferred to a test tube, beaker or other suitable container 
into which may be placed a dialysis bag containing a protein 
solution. However, any mechanism can be used to coordi- 
nate transfer of salt solution to and from the crystallization 
15 chamber(s) such as a software interlock programmed into 
the controller or any other mechanical interlock. 
The various dimensions, volumes and solution concen- 
trations can be varied to provide desirable crystallization 
characteristics. Various sensors can be placed in the crys- 
20 tallization chamber, in the syringes, or at appropriate posi- 
tions to detect crystallization. solution concentration, 
temperature, position, pressure or other variables. The out- 
puts of such sensors can be used to control the crystallization 
process. The “salt” solution can be any solution having ionic 
25 or chemical characteristics that permit crystallization of the 
protein, The concentration of salt solution in the crystalli- 
zation chamber(s) can be raised or lowered to a desired value 
for crystallization. The relative concentrations of salt solu- 
tion in the crystallization chamber(s) and in the solution 
30 chambers can be varied, based on crystallization conditions. 
Asecond salt solution may be placed in another salt solution 
chamber. The concentration of salt in this chamber may be 
different than that of the salt concentration in other salt 
solution chambers. 
A salt solution of appropriate concentration, to store the 
crystal for prolonged periods of time, may be placed in a salt 
solution reservoir. Fluid from this reservoir may be very 
slowly pumped into the actual protein containing area of the 
crystallization chamber through a very narrow bore access 
40 tube (c0.2 mm) or other suitable outlet. An equal volume of 
fluid from this area may be very slowly and concurrently 
pumped out of this area of the chamber through a very 
narrow bore access tube (c0.2 mm) or other suitable outlet. 
The invention may also be used to crystallize substances 
other than proteins. These substances include, but are not 
limited to nucleic acids, nucleic acids in combination with 
proteins, proteins bound to lipids or glycolipids, membrane- 
bound proteins, viruses and subcellular organdles. 
Substances other than proteins and salt solutions may be 
placed in the crystallization chamber or other suitable recep- 
tacle. Such substances include, but are not limited to cells, 
chemotactic factors, growth factors and cell culture media. 
The salt solution resevoirs may hold fluids other than salt 
55 solutions or other chemical solutions involved in crystalli- 
zation. Membranes other than those used in dialysis may be 
placed in the crystallization chamber or other suitable recep- 
tacle. 
In the preferred embodiment the temperature is not 
60 controlled, however a temperature controlling device may 
be used. Typical techniques may include using a Peltier 
cooler, a temperature controlled container, and heating coils 
imbedded in the system. 
In the preferred embodiment viewing and visual recording 
65 devices (to image the interior of the crystallization chamber 
14) are not shown, however any such devices are envisioned 
as well. Such devices may include, but are not limited to, a 
35 
4s 
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camera to take static photographs, a video-recording device, 
a magnifying device, and a magnifying device in tandem 
with a video-recording device. 
What is claimed: 
1. An apparatus for crystallizing proteins comprising: 
at least one crystallization chamber configured to contain 
a protein in a salt solution for crystallization of the 
protein; 
at least a first solution chamber and a second solution 
chamber, said first and second solution chambers being 
configured to contain respective salt solutions; 
first communicating means for communicating said first 
solution chamber with said crystallization chamber; 
second communicating means for communicating said 
second solution chamber with said crystallization 
chamber; 
first transfer means for selectively transferring salt solu- 
tion between said first solution chamber and said crys- 
tallization chamber; 
second transfer means for selectively transferring salt 
solution between said second solution chamber and 
said crystallization chamber; 
interlocking means for interlocking said first transfer 
means and said second transfer means to cause said first 
transfer means and said second transfer means to 
reversibly transfer equal volumes of salt solution into 
and out of said crystallization chamber. 
2. An apparatus as recited in claim 1, further comprising 
dynamic control means coupled to said first transfer means 
and said second transfer means for controlling the amount of 
salt solution transferred by said first transfer means and said 
second transfer means. 
3. Aprotein crystallization apparatus as recited in claim 2, 
comprising 
means for monitoring and dynamically controlling crys- 
tallization in said crystallization chamber in real time. 
4. Aprotein crystallization apparatus as recited in claim 2, 
means for selectively starting and stopping a crystalliza- 
5. An apparatus as recited in claim 2, wherein said first 
solution chamber and said first transfer means comprise a 
first syringe and said second solution chamber and said 
second transfer means comprise a second syringe. 
6. An apparatus as recited in claim 5,  wherein said first 
transfer means and second transfer means further comprise 
a motor operatively coupled to said first syringe and said the 
second syringe. 
7. An apparatus as recited in claim 6, wherein said 
interlocking means comprises a yoke operatively coupled 
between said motor and said first syringe and said second 
syringe. 
comprising 
tion process in said crystallization chamber. 
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8. An apparatus as recited in claim 7, further comprising 
a guide rod, said yoke being slidably mounted on the said 
guide rod. 
9. An apparatus as recited in claim 8, wherein said first 
and second transfer means further comprise a lead screw 
coupled to a shaft of said motor, said lead screw being 
threadably engaged with said yoke. 
10. An apparatus as recited and claim 6, wherein said 
control means is operatively coupled to said motor to control 
transfer of the protein solution. 
11. An apparatus as recited in claim 1, wherein said 
crystallization chamber comprises a container in which one 
of a membrane and permanent sieve is interposed between 
the salt solution and the protein solution. 
12. An apparatus for crystallizing proteins comprising: 
a crystallization chamber configured to contain a protein 
in a salt solution for crystallization of the protein; 
at least a first solution chamber and a second solution 
chamber, said first solution chamber and second solu- 
tion chamber being configured to contain respective 
salt solutions; 
a first conduit coupling said first solution chamber with 
said crystallization chamber; 
a second conduit coupling said second solution chamber 
with said crystallization chamber; 
a first transfer mechanism configured to selectively trans- 
fer salt solution between said first solution chamber and 
said crystallization chamber; 
a second transfer mechanism configured to selectively 
transfer salt solution between said second solution 
chamber and said crystallization chamber; 
an interlock coupling said first transfer mechanism and 
said second transfer mechanism to cause said first 
transfer mechanism and said second transfer mecha- 
nism to reversibly transfer equal volumes of salt solu- 
tion into and out of said crystallization chamber. 
13. An apparatus as recited in claim 12, further compris- 
ing a controller coupled to said first transfer mechanism and 
said second transfer mechanism to control the amount of salt 
solution transferred by said first transfer mechanism and said 
second transfer mechanism. 
14. An apparatus as recited in claim 12, wherein said 
crystallization chamber comprises a container and a dialysis 
bag disposed in said container said dialysis bag being 
configured to hold the protein. 
* * * * *  
